NASDAQ:ONVO - Organovo Stock Price, Forecast & News

Organovo's stock was trading at $0.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ONVO stock has increased by 13.4% and is now trading at $0.2949. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Organovo.

Organovo is scheduled to release its next quarterly earnings announcement on Monday, June 1st 2020. View our earnings forecast for Organovo.

Organovo Holdings Inc (NASDAQ:ONVO) released its earnings results on Thursday, August, 8th. The medical research company reported ($0.05) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.05). The medical research company earned $0.67 million during the quarter, compared to analysts' expectations of $0.77 million. Organovo had a negative net margin of 798.68% and a negative return on equity of 69.36%. View Organovo's earnings history.

News stories about ONVO stock have trended very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Organovo earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutOrganovo.

Organovo saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,286,300 shares, an increase of 14.9% from the February 27th total of 1,990,000 shares. Based on an average daily volume of 404,600 shares, the days-to-cover ratio is presently 5.7 days. Currently, 1.8% of the company's stock are sold short. View Organovo's Current Options Chain.

Some companies that are related to Organovo include CASI Pharmaceuticals (CASI), Tcr2 Therapeutics (TCRR), Cabaletta Bio (CABA), Eiger Biopharmaceuticals (EIGR), Jounce Therapeutics (JNCE), X4 Pharmaceuticals (XFOR), Dyadic International (DYAI), Verona Pharma (TARA), Windtree Therapeutics (WINT), Vaxart (VXRT), Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC), La Jolla Pharmaceutical (LJPC), LogicBio Therapeutics (LOGC) and Solid Biosciences (SLDB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), Aerojet Rocketdyne (AJRD), NVIDIA (NVDA), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Exelixis (EXEL), Micron Technology (MU), Anavex Life Sciences (AVXL), Novavax (NVAX) and General Electric (GE).

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ONVO stock can currently be purchased for approximately $0.29.

Organovo has a market capitalization of $38.48 million and generates $3.09 million in revenue each year. Organovo employs 70 workers across the globe. View additional information about Organovo.

The official website for Organovo is http://www.organovo.com/.

Organovo's mailing address is 440 STEVENS AVE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]